ClearPoint Neuro Announces Full Market Release of SmartFrame OR and ClearPoint PRISM 3T Laser Therapy System
| CLPT Stock | USD 15.75 0.14 0.88% |
Slightly above 63% of Clearpoint Neuro's investor base is looking to short. The analysis of overall sentiment of trading Clearpoint Neuro stock suggests that many investors are alarmed at this time. Clearpoint Neuro's investing sentiment can be driven by a variety of factors including economic data, Clearpoint Neuro's earnings reports, geopolitical events, and overall market trends.
Clearpoint |
SOLANA BEACH, Calif., June 01, 2024 -- ClearPoint Neuro, Inc. , a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine,
Read at benzinga.com
 |
Clearpoint Neuro Fundamental Analysis
We analyze Clearpoint Neuro's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clearpoint Neuro using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clearpoint Neuro based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Clearpoint Neuro is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Clearpoint Neuro Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Clearpoint Neuro stock to make a market-neutral strategy. Peer analysis of Clearpoint Neuro could also be used in its relative valuation, which is a method of valuing Clearpoint Neuro by comparing valuation metrics with similar companies.
Peers
Clearpoint Neuro Related Equities
| NARI | Inari Medical | 30.60 | ||||
| CTSO | Cytosorbents Crp | 10.64 | ||||
| APYX | Apyx Medical | 3.61 | ||||
| NPCE | Neuropace | 3.11 | ||||
| RCEL | Avita Medical | 3.10 | ||||
| INSP | Inspire Medical | 3.01 | ||||
| LUNG | Pulmonx Corp | 2.14 | ||||
| KIDS | Orthopediatrics Corp | 1.80 | ||||
| ELMD | Electromed | 1.76 | ||||
| LIVN | LivaNova PLC | 0.59 | ||||
| SRDX | SurModics | 0.48 | ||||
| INGN | Inogen | 1.14 | ||||
| TMCI | Treace Medical | 1.39 | ||||
| TELA | Tela Bio | 2.41 | ||||
| SGHT | Sight Sciences | 2.58 | ||||
| OM | Outset Medical | 9.29 |
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.